Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.

NCT05027386 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT05027386
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05027386 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
Lead sponsor
Sun Yat-sen University
Phase
Phase 1/2
Overall status
Completed
Start date
August 26, 2021
Completion date
February 4, 2026
Enrollment
125 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma